Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

R0531

Sigma-Aldrich

Ramatroban

≥98% (HPLC), solid

Sinonimo/i:

(+)-(3R)-3-[[(4-Fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid, BAY u3405

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

5 MG
CHF 174.00
25 MG
CHF 655.00

CHF 174.00

Check Cart for Availability
Richiedi un ordine bulk
Tutte le immagini(1)

Scegli un formato

Cambia visualizzazione
5 MG
CHF 174.00
25 MG
CHF 655.00

About This Item

Formula empirica (notazione di Hill):
C21H21FN2O4S
Numero CAS:
116649-85-5
Peso molecolare:
416.47
Numero MDL:
MFCD00887606
Codice UNSPSC:
51111800
ID PubChem:
329823986
NACRES:
NA.77

CHF 174.00

Check Cart for Availability
Richiedi un ordine bulk

Saggio

≥98% (HPLC)

Stato

solid

Colore

white

Solubilità

DMSO: ≥40 mg/mL
H2O: insoluble

Ideatore

Bayer

Temperatura di conservazione

2-8°C

Stringa SMILE

OC(=O)CCn1c2CC[C@H](Cc2c3ccccc13)NS(=O)(=O)c4ccc(F)cc4

InChI

1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
LDXDSHIEDAPSSA-OAHLLOKOSA-N

Azioni biochim/fisiol

Ramatroban aids in the reduction of myocardial ischemia-reperfusion injury, lipopolysaccharide-induced shock, and vagal neuroeffector transmission in the tracheal smooth muscle of experimental models. In addition, it also suppresses allergen and IgE antibody-mediated skin and nasal reactions and eosinophilia in animal models with asthma.[1]
Ramatroban is used for the treatment of allergic rhinitis as an antagonist of the thromboxane receptor.
Ramatroban is used for the treatment of allergic rhinitis as an antagonist of the thromboxane receptor. It is also an antagonist of the DP2 receptor with IC50 values of 100-170 nM. It is more potent at the DP2 receptor than the TP receptor by 4-5 fold. It is therefore a useful tool for the elucidation of PGD2/DP2 function in eosinophils, basophils, and other cells of the TH2 cell-type.

Caratteristiche e vantaggi

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H315,H319,H335

Classi di pericolo

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organi bersaglio

Respiratory system

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

dust mask type N95 (US), Eyeshields, Gloves

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
0000136711
0000136712
049K4719
0000136712
0000136711

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Eduardo Busto et al.
The Journal of organic chemistry, 77(10), 4842-4848 (2012-04-21)
A chemoenzymatic asymmetric route for the preparation of enantiopure (R)-ramatroban has been developed for the first time. The action of lipases and oxidoreductases has been independently studied, and both were found as excellent biocatalysts for the production of adequate chiral
J F Royer et al.
European journal of clinical investigation, 38(9), 663-671 (2008-10-08)
Chemoattractant receptor homologous molecule of Th2 cells (CRTH2) has been shown to mediate the chemotaxis of eosinophils, basophils and Th2-type T lymphocytes. The major mast cell product prostaglandin (PG) D(2) is considered to be the principal ligand of CRTH2. We
Tetsuro Wada et al.
Auris, nasus, larynx, 33(4), 455-460 (2006-08-11)
The pathogenesis of eosinophilic otitis media is not yet fully understood. The purpose of this paper is to describe the clinical course of our two patients with eosinophilic otitis media and to discuss the pathogenesis and treatment of this intractable
Hiromi Sugimoto et al.
European journal of pharmacology, 524(1-3), 30-37 (2005-11-01)
We previously showed that ramatroban (Baynastrade mark), a thromboxane A(2) (TxA(2)) antagonist, had inhibited prostaglandin D(2) (PGD(2))-stimulated human eosinophil migration mediated through activation of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). However, detailed pharmacological characterization of its inhibitory activity
Toshiaki Ishizuka et al.
Cardiovascular drug reviews, 22(2), 71-90 (2004-06-05)
It is known that thromboxane A2 (TXA2) contributes to various diseases such as bronchial asthma, ischemic heart disease, cerebrovascular disorders and allergic rhinitis. A number of TXA2 synthase inhibitors and TXA2 receptor (TP receptor) antagonists have been developed to treat
Visualizza tutti i documenti correlati

Articoli

Discover Bioactive Small Molecules for Lipid Signaling Research

Discover Bioactive Small Molecules for Lipid Signaling Research

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.